Single high-dose brachytherapy for giant osteosarcoma masses
Part of Cancer clinical trials.
This study tests a radiation treatment called brachytherapy, which delivers a high dose of radiation directly to the tumor. It is for people with osteosarcoma that cannot be removed by surgery and has not responded to other treatments. The goal is to shrink the tumor and control symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with osteosarcoma, a type of bone cancer.
- You are between 12 and 70 years old.
- Your tumor cannot be removed with surgery, and standard treatments like chemo, targeted therapy, or immunotherapy have not worked.
- Your tumor measures more than 5 centimeters (about 2 inches) across.
- You have not had radiation to the tumor area before, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
This trial tests removing the tumor with surgery first, then following up with chemotherapy. It's for people with a new, high-grade osteosarcoma in an arm or leg that hasn't spread.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
This trial tests a special dye that targets B7-H3, a protein found on osteosarcoma cells. Before your surgery, the dye is injected and helps surgeons see tumor edges more clearly, so they can remove all of the cancer while saving healthy tissue.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.